BJC Open article

British Journal of Cancer (2003) 89, 465–469. doi:10.1038/sj.bjc.6601153
Published online 29 July 2003

A medical nutriment has supportive value in the treatment of colorectal cancer

F Jakab1, Y Shoenfeld2, Á Balogh3, M Nichelatti4, A Hoffmann5, Zs Kahán6, K Lapis7, Á Mayer8, P Sápy9, F Szentpétery1, A Telekes5, L Thurzó6, A Vágvölgyi9 and M Hidvégi10

  1. 1Department of Surgery and Vascular Surgery, Uzsoki Teaching Hospital of Budapest, Hungary
  2. 2Department of Medicine ‘B’, Sackler Faculty of Medicine, Tel-Aviv University, Sheba Medical Center, Tel-Hashomer 52621, Israel
  3. 3Clinic of Surgery, University of Szeged, Hungary
  4. 4Biostatistics Unit, Associazione Malattie del Sangue, Hospital Niguarda Cà Granda, Milan, Italy
  5. 5Biromedicina First Hungarian Corporation for Cancer Research and Oncology, Budapest, Hungary
  6. 6Clinic of Oncotherapy, University of Szeged, Hungary
  7. 71st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
  8. 8Budapest Center of Onco-Radiology, Uzsoki Teaching Hospital of Budapest, Hungary
  9. 92nd Clinic of Surgery, University of Debrecen, Hungary
  10. 10Jewish University, Budapest, Hungary

Correspondence: Dr Y Shoenfeld, E-mail:

Received 21 November 2002; Revised 8 April 2003; Accepted 25 May 2003



MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%, P<0.01; new metastases: 7.6 vs 23.1%, P<0.01; deaths: 12.1 vs 31.7%, P<0.01). Survival analysis showed significant improvements in the MSC group regarding progression-free (P=0.0184) and overall survivals (P=0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.


fermented wheat germ extract; colorectal cancer; cohort study; progression-free and overall survival